Lu-177 production begins at Canada’s Bruce NPP

November 1, 2022, 1:27PMNuclear News
Bruce's Unit 7 is now producing Lutetium-177, used in targeted cancer therapeutics. (Photo: Bruce Power)

An international collaboration between Bruce Power, Isogen (a Kinectrics and Framatome company), and ITM Isotope Technologies Munich SE (ITM) announced they have begun commercial production of lutetium-177 using Unit 7 of the Bruce nuclear power plant in Kincardine, Ontario. According to the companies, this marks the first time a commercial power reactor has been used to commercially produce short-lived medical radioisotopes.

To continue reading, log in or create a free account!

Related Articles

Constellation appoints new nuclear chief

September 5, 2025, 7:01AMNuclear News

Longtime nuclear industry executive Chris Mudrick has been named the new chief nuclear officer at Constellation Energy, effective September 29. He will take over the position from Dave...

Nuclear's future discussed at MURR expansion

April 7, 2025, 3:05PMANS News

ANS Executive Director/CEO Craig Piercy recently spoke on nuclear power’s potential for answering today’s energy demands as part of the Distinguished Lecture Series at the University of...